AGC BiologicsSNY
ImmunologyMetabolicOncology120 cited findings · profile updated 2026-08-25
45.42 USDnot live — refreshed daily
About AGC Biologics
AGC Biologics (SNY) has a therapeutic focus that includes oncology, immunology, and metabolic disorders. In oncology, the company's drug Kevzara was studied, with an incidence of Grade 3 or 4 neutropenia of 28.5% in Portion 1 of the DRI13925 trial. In the same trial, participants with Grade 3 or 4 neutropenia included 8 in Group B, 6 in Dose 3, 3 in Dose 1, and 3 in Dose 2. Another study, MSC12665, reported an incidence of grade 3 or 4 neutropenia of 7.1% and 7.7%. Jevtana was also studied, showing various adverse events such as metabolism and nutrition disorders (all grades) at 15.9% and 23.7%, and Grade >=3 at 2.2% and 4.9%. Musculoskeletal and connective tissue disorders (all grades) were observed at 39.9% and 43.4%, with Grade >=3 at 9.4% and 8.1%. Renal and urinary disorders (all grades) were 11.3% and 30.7%, with Grade >=3 at 2.4% and 8.6%. General disorders and administration site conditions (all grades) were 50.1% and 68.5%, with Grade >=3 at 9.7% and 13.5%.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| Incidence of Grade 3 or 4 neutropenia | 28.5 % | Sanofi — Kevzara EMA EPAR variation assessment report (EMEA/H/C/004254, p.35 |
| Proportion of patients with EASI-75 at week 52 (Subset 3, dupilumab 300 mg Q2W + TCS) | 52.4 % | Sanofi — Dupixent EMA EPAR public assessment report (EMEA/H/C/004390,, p.42 |
| Proportion of patients with EASI-75 at week 52 (Subset 3, placebo + TCS) | 18.6 % | Sanofi — Dupixent EMA EPAR public assessment report (EMEA/H/C/004390,, p.42 |
| Grade 3 (severe) TEAEs (Teplizumab) | 7.8 % | Sanofi — Teizeild EMA EPAR public assessment report (EMEA/H/C/005496,, p.167 |
| Grade 3 (severe) TEAEs (Control) | 1.7 % | Sanofi — Teizeild EMA EPAR public assessment report (EMEA/H/C/005496,, p.167 |
| metabolism and nutrition disorders (all grades) | 15.9 % | Sanofi — Jevtana EMA EPAR public assessment report (EMEA/H/C/002018, 2, p.56 |
Key projects
- Kevzara (active polyarticular juvenile idiopathic arthritis)
Kevzara is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA; rheumatoid factor positive or negative polyarthritis and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with conventional synthetic DMARDs (csDMARDs).
- Kevzara
Incidence of Grade 3 or 4 neutropenia was 28.5% in DRI13925 Portion 1.
- Jevtana
Metabolism and nutrition disorders (all grades) were observed at 15.9% in EFC6193.
- Dupixent
The proportion of patients with EASI-75 at week 52 was 52.4% in R668-AD-1224 (Subset 3, dupilumab 300 mg Q2W + TCS).
- Teizeild
Grade 3 (severe) TEAEs were 7.8% in the Teplizumab group.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Immunology research library →